Invivyd Announces Presentation at the World Vaccine Congress Washington

Core Insights - Invivyd, Inc. presented advancements in monoclonal antibody (mAb) therapies at the World Vaccine Congress, emphasizing the need for treatments that can adapt to rapidly evolving viral threats [1][8] - The company aims to address the limitations of current vaccinology by developing mAb treatments for vulnerable populations, focusing on scalability, access, and economic factors [2] Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [5] - The company utilizes a proprietary integrated technology platform to develop and adapt high-quality antibodies [5] Event Details - The World Vaccine Congress is recognized as the largest global meeting for vaccine discussions, featuring a wide range of topics and speakers from various sectors [3] - The event facilitates collaboration among scientists, government officials, and manufacturers to drive progress in vaccine development [3]